Burke N - Search Results

1

Targeting mitochondria for cardioprotection: examining the benefit for patients.

Dongworth RK, Hall AR, Burke N, Hausenloy DJ. Dongworth RK, et al. Among authors: burke n. Future Cardiol. 2014 Mar;10(2):255-72. doi: 10.2217/fca.14.6. Future Cardiol. 2014. PMID: 24762253 Review.

2

Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease.

Hall AR, Burke N, Dongworth RK, Hausenloy DJ. Hall AR, et al. Among authors: burke n. Br J Pharmacol. 2014 Apr;171(8):1890-906. doi: 10.1111/bph.12516. Br J Pharmacol. 2014. PMID: 24328763 Free PMC article. Review.

3

Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction.

Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM, Dorn GW II, Yellon DM, Hausenloy DJ. Hall AR, et al. Among authors: burke n. Cell Death Dis. 2016 May 26;7(5):e2238. doi: 10.1038/cddis.2016.139. Cell Death Dis. 2016. PMID: 27228353 Free PMC article.

4

Loss of PINK1 increases the heart's vulnerability to ischemia-reperfusion injury.

Siddall HK, Yellon DM, Ong SB, Mukherjee UA, Burke N, Hall AR, Angelova PR, Ludtmann MH, Deas E, Davidson SM, Mocanu MM, Hausenloy DJ. Siddall HK, et al. Among authors: burke n. PLoS One. 2013 Apr 29;8(4):e62400. doi: 10.1371/journal.pone.0062400. Print 2013. PLoS One. 2013. PMID: 23638067 Free PMC article.

5

OPA1 in Cardiovascular Health and Disease.

Burke N, Hall AR, Hausenloy DJ. Burke N, et al. Curr Drug Targets. 2015;16(8):912-20. doi: 10.2174/1389450116666150102113648. Curr Drug Targets. 2015. PMID: 25557256 Review.

6

Correction: Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction.

Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM, Dorn GW 2nd, Yellon DM, Hausenloy DJ. Hall AR, et al. Among authors: burke n. Cell Death Dis. 2021 Jun 30;12(7):660. doi: 10.1038/s41419-021-03946-8. Cell Death Dis. 2021. PMID: 34193829 Free PMC article. No abstract available.

7

Intrinsic cardiac ganglia and acetylcholine are important in the mechanism of ischaemic preconditioning.

Pickard JMJ, Burke N, Davidson SM, Yellon DM. Pickard JMJ, et al. Among authors: burke n. Basic Res Cardiol. 2017 Mar;112(2):11. doi: 10.1007/s00395-017-0601-x. Epub 2017 Jan 13. Basic Res Cardiol. 2017. PMID: 28091727 Free PMC article.

8

Exogenous Administration of Recombinant MIF at Physiological Concentrations Failed to Attenuate Infarct Size in a Langendorff Perfused Isolated Mouse Heart Model.

Rossello X, Burke N, Stoppe C, Bernhagen J, Davidson SM, Yellon DM. Rossello X, et al. Among authors: burke n. Cardiovasc Drugs Ther. 2016 Oct;30(5):445-453. doi: 10.1007/s10557-016-6673-2. Cardiovasc Drugs Ther. 2016. PMID: 27335054 Free PMC article.

9

Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis.

Bromage DI, Pickard JM, Rossello X, Ziff OJ, Burke N, Yellon DM, Davidson SM. Bromage DI, et al. Among authors: burke n. Cardiovasc Res. 2017 Mar 1;113(3):288-297. doi: 10.1093/cvr/cvw219. Cardiovasc Res. 2017. PMID: 28028069 Free PMC article. Review.

10

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators. Newby LK, et al. Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12. Lancet. 2014. PMID: 24930728 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

423 results

Search Page